Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4

Figure 1

A potential protein-protein non-kinase functional binding site in Cdk4 not present in Cdk2 or Cdk6. A - Relative proteomic expression by Western blotting, of Cdk4, Cdk6 and Cdk2 compared to Cdk1 on 16 human in vitro cancer cell lines of widely differing histological subtype by quantitative Western blotting as previously described [20]. Primary antibodies were Cdk1 - mouse monoclonal sc-54 (1/250), Cdk2 - (M2) rabbit polyclonal sc-163 (1/250), Cdk4 - rabbit polyclonal sc-260 (1/250) Cdk6 - rabbit polyclonal sc-260 at 1/250, (see methods). B - Upper panels: Endogenous Cdk1 follows a similar time course and increase in proteomic expression as exogenous Cdk4 induced by 1 μM muristerone in 2780 pvrg-pINDK4 clone 1D cells (see methods). Lower panels Western blotting for total retinoblastoma protein (pRb 105) and hyperphosphorylated retinoblastoma protein (p110) following exposure of 2780 pvrgpINDK4 clone 1D cells to 1 μM muristerone. C - Location of the PRGPRP central hexameric amino acid sequence (residues 249 - 260) of FPPRGPRPVQS within an externalised loop in the C' terminal region, distant from the classically described kinase domain of Cdk4.

Back to article page